Drug Approval | April 08, 2026
Lupin wins USFDA nod for generic Dapagliflozin tablets
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The patient, suffering from calcific severe aortic stenosis—a dangerous narrowing of the heart valve caused by calcium buildup—had run out of standard treatment options
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Subscribe To Our Newsletter & Stay Updated
